A randomised double-blind placebo-controlied trial of intravenous methylprednisolone versus (range 19-72) and a mean duration of disease of 5-4 years (range 0-1-27). Informed consent was obtained from each patient and the study was approved by the local ethics committee.
A randomised double-blind placebo-controlied trial of intravenous methylprednisolone versus Following randomisation, each patient received either 500 mg of intravenous methylprednisolone in 100 ml of normal saline by slow intravenous infusion together with five placebo tablets, or 100 ml of placebo intravenously with five 100 mg tablets of methylprednisolone orally, for five days. All patients were scored by a "blind" assessor at days 0, 5 and 28 using the disability and functional rating score devised by Kurtzke;8 specific enquiries were made regarding possible adverse effects. ( There were no major side effects in either group. Minor side effects including headache, indigestion, acne, dizziness, flushed feeling, phlebitis, ankle oedema and mild depression were equally distributed in both groups. A metallic taste after injection was only present in the intravenous group. There was no increase in gastrointestinal symptoms in the group that received methylprednisolone orally.
Discussion
Most neurologists use steroid therapy in one form or another to treat patients with MS in relapse, although some hold the view that any benefit is at best only marginal.9 Intravenous methylprednisolone has been used successfully for several years but this form of therapy may be inconvenient for the patient and wasteful of hospital resources. This study suggests that oral methylprednisolone at an equivalent high dose is as effective and safe as intravenous treatment. The treatment response was the same in the orally treated patients as in the intravenous group. There were no serious adverse effects in either group; the frequency of minor side effects was equal and in particular there was no excess of upper gastrointestinal reactions in the oral group.
In an earlier controlled trial of intravenous methylprednisolone a significant improvement was seen compared with placebo when 22 patients in relapse were evaluated.3 Our study had the power to detect a 25% difference in disability grade improvement between the oral and intravenous treatments but would have required 98 randomisations to detect a 10% difference. Thus a large study is desirable which could include another arm of low dose prednisolone and should be ideally placebo controlled.
This experience in patients with MS parallels similar findings when high dose oral methylprednisolone has been evaluated in patients with rheumatoid arthritis'0 and in children with idiopathic thrombo cytopenia purpura."' Oral medication has obvious logistic advantages over intravenous therapy, and our study suggests that in MS it is as safe and no less effective.
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